Investing

Boston Scientific (BSX): Stent Problems Aren't Enough

There has been plenty of press about the issues of whether coated stents made by Boston Scientific (BSX) and Johnson & Johnson (JNJ) can cause clotting problems. Several studies show that use of these stents by cardiologists has dropped sharply.

So has BSX stock price. The shares are down 15% over the last year.

But, the stent problems were not enough. A federal court has ruled that some of the product liability claims over heart defibrillators that the company’s Guidant unit made can proceed. "This case concerns the issues of whether, how, and to whom information was shared … about a device with an alleged defect," Judge Frank wrote in his ruling.

For BSX shareholders the bad news is that the company will have to continue to fight a two front war, and that usually does not come out well.

Douglas A. McIntyre

Essential Tips for Investing: Sponsored

A financial advisor can help you understand the advantages and disadvantages of investment properties. Finding a qualified financial advisor doesn’t have to be hard. SmartAsset’s free tool matches you with up to three financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you. If you’re ready to find an advisor who can help you achieve your financial goals, get started now.

Investing in real estate can diversify your portfolio. But expanding your horizons may add additional costs. If you’re an investor looking to minimize expenses, consider checking out online brokerages. They often offer low investment fees, helping you maximize your profit.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.